{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:19:04Z","timestamp":1788347944189,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute leukemia is the most common cancer in children, highlighting the importance of early diagnosis. RECAF is an AFP receptor that is abnormally re-expressed in various malignant tumors, serving as a promising biomarker for tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to assess the clinical utility of RECAF expression by flow cytometry immunophenotyping in pediatric de novo acute leukemia patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study was conducted in 80 pediatric patients with acute leukemia, comprising 40 newly diagnosed ALL patients, 40 newly diagnosed AML patients, and 40 age- and sex-matched non-malignant control subjects. Flow cytometric analysis for the Acute Leukemia panel and RECAF expression was performed on all subjects, along with other laboratory and clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our study revealed that RECAF expression was significantly higher in patients with acute leukemia than in controls. We also established a cutoff of \u2265\u200913.31% for positive RECAF expression by flow cytometry to distinguish RECAF-positive acute leukemia patients from FECAF-negative patients and normal controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that RECAF could be an important biomarker for differentiating leukemic blasts and may become a useful tool for monitoring measurable residual disease in the future. Such advancements have the potential to improve clinical outcomes and enhance patient monitoring and management for this high-risk group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00404-4","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:06:21Z","timestamp":1788347181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pilot study on RECAF (Receptor for Alpha-Fetoprotein) expression in pediatric acute leukemia: insights from flow cytometry analysis"],"prefix":"10.1186","volume":"38","author":[{"given":"Soha Raouf","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Hany","family":"Mohammady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7046-6146","authenticated-orcid":false,"given":"Shams ElDoha Galal ElDin","family":"Zaiema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"3","key":"404_CR1","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.3892\/mmr.2016.4876","volume":"13","author":"L -Cao","year":"2016","unstructured":"Cao L, Wang N, Pan J, Hu S, Zhao W, He H, Chai Y. Clinical significance of microRNA-34b expression in pediatric acute leukemia. Mol Med Rep. 2016;13(3):2777\u201384.","journal-title":"Mol Med Rep"},{"issue":"6","key":"404_CR2","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T -Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay MJBCJ. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood cancer J. 2017;7(6):e577\u2013577.","journal-title":"Blood cancer J"},{"issue":"4","key":"404_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000496097","volume":"141","author":"BJ -Bain","year":"2019","unstructured":"Bain BJ, B\u00e9n\u00e9 MC. Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia. Acta Haematol. 2019;141(4):232\u201344.","journal-title":"Acta Haematol"},{"key":"404_CR4","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.clml.2016.02.032","volume":"16","author":"SA -Awad","year":"2016","unstructured":"Awad SA, Kamel MM, Ayoub MA, Kamel AM, Elnoshokaty EH, Hifnawi E, N. Immunophenotypic characterization of cytogenetic subgroups in Egyptian pediatric patients with B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2016;16:S19\u201324.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"404_CR5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.6004\/jnccn.2019.0024","volume":"17","author":"PA -Brown","year":"2019","unstructured":"Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Shah B. NCCN guidelines insights: acute lymphoblastic leukemia, Version 1.2019: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2019;17(5):414\u201323.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"404_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cyto.b.21518","volume":"94","author":"MN Dworzak","year":"2018","unstructured":"Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, International-BFM\u2010FLOW\u2010network. AIEOP\u2010BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia. Cytometry Part B: Clin Cytometry. 2018;94(1):82\u201393.","journal-title":"Cytometry Part B: Clin Cytometry"},{"key":"404_CR7","doi-asserted-by":"publisher","unstructured":"Li W. Measurable residual disease testing in acute leukemia: technology and clinical significance. Exon. 2022;79\u2013100. https:\/\/doi.org\/10.36255\/exon-publications-leukemia-measurable-residual-disease.","DOI":"10.36255\/exon-publications-leukemia-measurable-residual-disease"},{"key":"404_CR8","unstructured":"Moro R. The alpha-fetoprotein receptor (RECAF): characterization and potential uses for cancer diagnosis and therapy. Alpha-fetoprotein: Funct Clin Appl. 2016;241\u201376."},{"issue":"20","key":"404_CR9","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.3390\/cancers13205096","volume":"13","author":"Y -Xu","year":"2021","unstructured":"Xu Y, Guo Q, Wei L. The emerging influences of alpha-fetoprotein in the tumorigenesis and progression of hepatocellular carcinoma. Cancers. 2021;13(20):5096.","journal-title":"Cancers"},{"key":"404_CR10","unstructured":"Adigun OO, Yarrarapu SNS, Zubair M, Khetarpal S. Alpha-fetoprotein analysis. StatPearls. StatPearls Publishing. 2024."},{"issue":"6","key":"404_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/bjc.1985.123","volume":"51","author":"M -Hajeri-Germond","year":"1985","unstructured":"Hajeri-Germond M, Naval J, Trojan J, Uriel J. The uptake of alpha-foetoprotein by C-1300 mouse neuroblastoma cells. Br J Cancer. 1985;51(6):791\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"404_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0736-5748(84)90005-4","volume":"2","author":"R -Moro","year":"1984","unstructured":"Moro R, Fielitz W, Esteves A, Grunberg J, Uriel J. In vivo uptake of heterologous alphafetoprotein and serum albumin by ependymal cells of developing chick embryos. Int J Dev Neurosci. 1984;2(2):143\u20138.","journal-title":"Int J Dev Neurosci"},{"issue":"1","key":"404_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00006231-198401000-00002","volume":"5","author":"R -Moro","year":"1984","unstructured":"Moro R, Heuguerot C, Vercelli-Retta J, Fielitz W, Lopez JJ, Roca R. The use of radioiodinated alpha-fetoprotein for the scintigraphic detection of mouse mammary carcinomas. Nucl Med Commun. 1984;5(1):13\u20137.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"404_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/bjc.1983.181","volume":"48","author":"J -Uriel","year":"1983","unstructured":"Uriel J, Poupon MF, Geuskens M. Alphafoetoprotein uptake by cloned cell lines derived from a nickel-induced rat rhabdomyosarcoma. Br J Cancer. 1983;48(2):261\u20139.","journal-title":"Br J Cancer"},{"issue":"11","key":"404_CR15","first-page":"5314","volume":"44","author":"J -Uriel","year":"1984","unstructured":"Uriel J, Villacampa MJ, Moro R, Naval J, Failly-Cr\u00e9pin C. Uptake of Radiolabeled \u03b1-Fetoprotein by Mouse Mammary Carcinomas and Its Usefulness in Tumor Scientigraphy. Cancer Res. 1984;44(11):5314\u20139.","journal-title":"Cancer Res"},{"issue":"4","key":"404_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5045\/br.2020.2020070","volume":"55","author":"HA -Sedky","year":"2020","unstructured":"Sedky HA, Youssef SR, Gamal DA, Houssein HF, Elsalakawy WA. First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B-NHL\/CLL patients. Blood Res. 2020;55(4):253\u201361.","journal-title":"Blood Res"},{"issue":"10","key":"404_CR17","doi-asserted-by":"publisher","first-page":"101042831773481","DOI":"10.1177\/1010428317734815","volume":"39","author":"J -Tcherkassova","year":"2017","unstructured":"Tcherkassova J, Tsurkan S, Smirnova G, Borisova J, Moro R, Treshalina H. Binding characterization of the targeting drug AIMPILA to AFP receptors in human tumor xenografts. Tumor Biology. 2017;39(10):1010428317734815.","journal-title":"Tumor Biology"},{"issue":"4","key":"404_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s13277-011-0186-1","volume":"32","author":"J -Tcherkassova","year":"2011","unstructured":"Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A, Moro R. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumor Biology. 2011;32(4):831\u20138.","journal-title":"Tumor Biology"},{"issue":"11","key":"404_CR19","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.3390\/cancers13112607","volume":"13","author":"S -Zahnreich","year":"2021","unstructured":"Zahnreich S, Schmidberger H. Childhood cancer: occurrence, treatment and risk of second primary malignancies. Cancers. 2021;13(11):2607.","journal-title":"Cancers"},{"issue":"10230","key":"404_CR20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F -Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362.","journal-title":"Lancet"},{"issue":"20","key":"404_CR21","first-page":"2391","volume":"127","author":"DA -Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau L, Vardiman MM, J. W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood J Am Soc Hematol. 2016;127(20):2391\u2013405.","journal-title":"Blood J Am Soc Hematol"},{"key":"404_CR22","unstructured":"Kumar S. Correlation Between Morphological and Cytochemical Diagnosis with Flowcytometric Analysis in Acute Leukemia (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India). 2019."},{"key":"404_CR23","doi-asserted-by":"crossref","unstructured":"Li W. Flow cytometry in the diagnosis of leukemias. 2022.","DOI":"10.36255\/exon-publications-leukemia-flow-cytometry"},{"issue":"1","key":"404_CR24","first-page":"9049252","volume":"2018","author":"X -Wang","year":"2018","unstructured":"Wang X, Wang Q. Alpha-fetoprotein and hepatocellular carcinoma immunity. Can J Gastroenterol Hepatol. 2018;2018(1):9049252.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"3","key":"404_CR25","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3390\/ijms24032539","volume":"24","author":"J -G\u0142owska-Ciemny","year":"2023","unstructured":"G\u0142owska-Ciemny J, Szyma\u0144ski M, Kuszerska A, Malewski Z, von Kaisenberg C, Kocy\u0142owski R. The role of alpha-fetoprotein (AFP) in contemporary oncology: The path from a diagnostic biomarker to an anticancer drug. Int J Mol Sci. 2023;24(3):2539.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"404_CR26","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/s41375-023-01962-5","volume":"37","author":"R Alaggio","year":"2023","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, de Oliveira Araujo IB, Berti E, Xiao W. Correction:The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms Leukemia. 2022; 36 (7): 1720\u20131748. Leukemia. 2023;37(9):1944\u201351.","journal-title":"Leukemia"},{"issue":"3","key":"404_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12185-024-03781-5","volume":"121","author":"K -Karube","year":"2025","unstructured":"Karube K, Satou A, Kato S. New classifications of B-cell neoplasms: A comparison of 5th WHO and International Consensus classifications. Int J Hematol. 2025;121(3):331\u201341.","journal-title":"Int J Hematol"},{"key":"404_CR28","doi-asserted-by":"crossref","unstructured":"Moro R, Gulyaeva\u2013Tcherkassova J, Stieber P. Increased alpha-fetoprotein receptor in the serum of patients with early-stage breast cancer. Curr Oncol. 2012;19(1):e1.","DOI":"10.3747\/co.19.979"},{"key":"404_CR29","doi-asserted-by":"publisher","first-page":"582218","DOI":"10.3389\/fnana.2020.582218","volume":"14","author":"S -Zaqout","year":"2020","unstructured":"Zaqout S, Becker LL, Kaindl AM. Immunofluorescence staining of paraffin sections step by step. Front Neuroanat. 2020;14:582218.","journal-title":"Front Neuroanat"},{"key":"404_CR30","doi-asserted-by":"publisher","first-page":"1165870","DOI":"10.3389\/fimmu.2023.1165870","volume":"14","author":"C -Aparicio-Perez","year":"2023","unstructured":"Aparicio-Perez C, Carmona M, Benabdellah K, Herrera C. Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL. Front Immunol. 2023;14:1165870.","journal-title":"Front Immunol"},{"issue":"2","key":"404_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/ijlh.14007","volume":"45","author":"S Gajendra","year":"2023","unstructured":"Gajendra S, Gupta R, Thakral D, Gupta SK, Jain G, Bakhshi S, Upadhyay AD. CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3\u2010ITD mutations. Int J Lab Hematol. 2023;45(2):221\u20138.","journal-title":"Int J Lab Hematol"},{"key":"404_CR32","doi-asserted-by":"publisher","unstructured":"Tsurkan S, Tcherkassova J, Gorbunova V, Treshalina H, Grigorieva EY. New drug AIMPILA targeted to AFP receptor. Oral anticancer therapy and biodistribution in vivo. 2018. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.e24232.","DOI":"10.1200\/JCO.2018.36.15_suppl.e24232"},{"issue":"1","key":"404_CR33","first-page":"709049","volume":"2012","author":"S Sarojini","year":"2012","unstructured":"Sarojini S, Tamir A, Lim H, Li S, Zhang S, Goy A, Suh KS. Early detection biomarkers for ovarian cancer. J Oncol. 2012;2012(1):709049.","journal-title":"J Oncol"},{"key":"404_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-981-16-5759-7_11","volume-title":"Cancer biomarkers in diagnosis and therapeutics","author":"KA -Janjua","year":"2022","unstructured":"Janjua KA, Shahzad R, Shehzad A. Development of novel cancer biomarkers for diagnosis and prognosis. Cancer biomarkers in diagnosis and therapeutics. Singapore: Springer Nature Singapore. 2022;277\u2013343. https:\/\/doi.org\/10.1007\/978-981-16-5759-7_11."}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00404-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00404-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00404-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:06:23Z","timestamp":1788347183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00404-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00404-4","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants or their guardians provided written informed consent in line with Ain Shams University (ASU) ethical regulations and ICH-GCP guidelines. The ASU Ethical Committee approved all protocols used. Throughout the study, confidentiality and privacy were strictly maintained. Ethical approval license: FMASU MS 590\/2022.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consents for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"66"}}